CN108913695B - Zeb1在人心脏成纤维细胞中的应用 - Google Patents
Zeb1在人心脏成纤维细胞中的应用 Download PDFInfo
- Publication number
- CN108913695B CN108913695B CN201810821050.4A CN201810821050A CN108913695B CN 108913695 B CN108913695 B CN 108913695B CN 201810821050 A CN201810821050 A CN 201810821050A CN 108913695 B CN108913695 B CN 108913695B
- Authority
- CN
- China
- Prior art keywords
- zeb1
- mir
- fibroblasts
- cardiac fibroblasts
- cardiac
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101000785626 Homo sapiens Zinc finger E-box-binding homeobox 1 Proteins 0.000 title abstract description 66
- 102100026457 Zinc finger E-box-binding homeobox 1 Human genes 0.000 title abstract description 63
- 210000002950 fibroblast Anatomy 0.000 title abstract description 23
- 210000001054 cardiac fibroblast Anatomy 0.000 claims abstract description 49
- 210000004027 cell Anatomy 0.000 claims abstract description 42
- 108091024411 miR-590 stem-loop Proteins 0.000 claims abstract description 40
- 101150074545 Zeb1 gene Proteins 0.000 claims description 13
- 108020004459 Small interfering RNA Proteins 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 abstract description 19
- 102000008186 Collagen Human genes 0.000 abstract description 12
- 108010035532 Collagen Proteins 0.000 abstract description 12
- 230000015572 biosynthetic process Effects 0.000 abstract description 12
- 229920001436 collagen Polymers 0.000 abstract description 12
- 230000035755 proliferation Effects 0.000 abstract description 12
- 238000003786 synthesis reaction Methods 0.000 abstract description 12
- 230000006870 function Effects 0.000 abstract description 11
- 230000005012 migration Effects 0.000 abstract description 11
- 238000013508 migration Methods 0.000 abstract description 11
- 230000004069 differentiation Effects 0.000 abstract description 10
- 108091070501 miRNA Proteins 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 9
- 239000002679 microRNA Substances 0.000 abstract description 8
- 208000010125 myocardial infarction Diseases 0.000 abstract description 5
- 206010016654 Fibrosis Diseases 0.000 abstract description 4
- 230000004761 fibrosis Effects 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 description 20
- 239000000243 solution Substances 0.000 description 16
- 238000011529 RT qPCR Methods 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 238000001890 transfection Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 108020005345 3' Untranslated Regions Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000012795 verification Methods 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 108700008625 Reporter Genes Proteins 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000005089 Luciferase Substances 0.000 description 5
- 206010028594 Myocardial fibrosis Diseases 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000019305 fibroblast migration Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010019668 Hepatic fibrosis Diseases 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000002452 interceptive effect Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000000651 myofibroblast Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000004055 small Interfering RNA Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010007945 Smad Proteins Proteins 0.000 description 2
- 102000007374 Smad Proteins Human genes 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101000667272 Dictyostelium discoideum Homeobox protein Wariai Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108091035710 E-box Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开一种ZEB1在人心脏成纤维细胞中的应用。本发明以ZEB1为研究对象,合成ZEB1干扰小片段,转染心脏成纤维细胞,发现ZEB1促进心脏成纤维细胞增殖、迁移、分化与胶原合成,还通过控制其表达的miR‑590‑3p在心脏成纤维细胞中的功能来进行研究;本发明干扰ZEB1后,验证能够回复由miR‑590‑3p引起的细胞功能表型,表明ZEB1在心脏成纤维细胞中是miR‑590‑3p的一个重要功能靶标,miR‑590‑3p可通过ZEB1来调节成纤维细胞的功能。本发明通过ZEB1和其靶向的miRNA在心脏成纤维细胞的应用,对于研究心肌梗死后的纤维化机制具有很好的应用价值。
Description
技术领域
本发明属于细胞工程和基因工程技术领域,特别涉及一种ZEB1在人心脏成纤维细胞中的应用。
背景技术
心肌梗死状动脉的血液流动不畅,心肌长时间缺氧、缺血而导致的局部心肌坏死。在心肌梗死发生的早期,细胞外基质合成和沉积能加强心脏的收缩力,形成瘫痕防止心脏破裂,在一定程度上改善心脏功能;但是在疾病的后期,由于细胞外基质的合成过多,在心脏组织中大量积累,导致心肌纤维化的发生。心脏成纤维细胞在心肌纤维化过程中大量增殖,同时分化为肌成纤维细胞,肌成纤维细胞合成大量胶原等成分堆积于心肌间,致使心肌组织中胶原纤维降解异常、各种胶原比例失衡和间质与血管周围的蛋白积累过度。因此,心脏成纤维细胞是心肌纤维化过程的重要效应细胞,它的功能改变能影响心肌纤维化进程。
锌指E盒结合的同源盒蛋白1(Zinc finger E-box binding homeobox 1,ZEB1)位于人染色体10p11.2上,是非常重要的一种细胞核转录因子。TGF-β是重要的致纤维化因子,ZEB1的基因结构上含有一个能与Smad蛋白结合的区域,可与磷酸化的Smad蛋白结合,从而促进TGF-β的活化转录。此结果说明,ZEB1可能参与调控器官的纤维化过程。研究发现在肝纤维化的大鼠模型中静脉注射重组ZEB1蛋白,HE和Masson染色结果显示,炎症与肝纤维化程度有所加重,纤维间距变宽,并且TGF-β表达水平上调,这些结果说明了ZEB1也许可以通过激活化某些途径促进TGF-β的转录进而促进大鼠肝纤维化进程。
微小核糖核酸(microRNA,miRNA)是一类内源性非编码单链小分子RNA,长度约为22个核苷酸,可通过与信使核糖核酸(Messenger Ribonucleic Acid,mRNA)的3′非翻译区(untranslated region,UTR)不同程度的互补配对,诱导靶基因mRNA降解或抑制翻译,从而在转录后水平调控靶基因的表达。
发明内容
为了克服现有技术的缺点与不足,本发明的首要目的在于提供一种ZEB1在人心脏成纤维细胞中的应用。以确定ZEB1对人心脏成纤维细胞功能的调节作用。
通过基因工程技术改变ZEB1基因在成纤维细胞的表达量,进而影响成纤维细胞增殖、迁移、胶原合成与分化;通过生物信息学软件预测该基因靶向的miRNA,研究该miRNA的功能,来达到ZEB1在人心脏成纤维细胞中应用的目的。
本发明的另一目的在于提供抑制ZEB1基因的小干扰RNA片段(siRNA)。
本发明的目的通过下述技术方案实现:
本发明提供一种ZEB1在人心脏成纤维细胞中的应用。
本发明提供抑制ZEB1基因的siRNA,序列如下:
si-ZEB1-1:5'-GGCAAGUGUUGGAGAAUAA-3';
si-ZEB1-2:5'-CCAGAAAUACACAGGGUUA-3';
si-ZEB1-3:5'-GGACAGCACAGUAAAUCUA-3';
本发明提供靶向ZEB1基因的miRNA,序列如下:
miR-590-3p:5'-UAAUUUUAUGUAUAAGCUAGU-3';
在心脏成纤维细胞中补充抑制ZEB1基因的小干扰RNA片段后,能回复由miR-590-3p引起的细胞功能表型。
验证结果如下:
1、合成3对干扰ZEB1基因的小片段/对照(si-ZEB1/si-ZEB1-NC),转染干扰小片段到成纤维细胞中(转染浓度为50nM),qRT-PCR检测其干扰效率,最终确定干扰效果较好的si-ZEB1-2小片段进行后续实验。
si-ZEB1-1:5'-GGCAAGUGUUGGAGAAUAA-3';
si-ZEB1-2:5'-CCAGAAAUACACAGGGUUA-3';
si-ZEB1-3:5'-GGACAGCACAGUAAAUCUA-3';
2、干扰ZEB1基因小片段(si-ZEB1-2)转染心脏成纤维细胞,研究其对人心脏成纤维细胞增殖、迁移、分化与胶原合成的应用。通过EdU法、Transwell、qRT-PCR与Westernblotting分别检测ZEB1受到si-ZEB1-2小片段干扰后心脏成纤维细胞增殖、迁移、分化与胶原合成情况,发现ZEB1促进纤维细胞增殖与迁移,促进心脏成纤维细胞分化为肌成纤维细胞与合成Ⅰ型与Ⅲ型胶原。
3、通过TargetScan、MiRanda、RNAhybrid 3个生物信息学软件预测调控ZEB1的miRNA,发现ZEB1的3'UTR区含有miR-590-3p结合位点,分别扩增ZEB1的野生型3'UTR区及与miR-590-3p种子区结合位点突变的突变型3'UTR区,并将其连接到pmirGLO真核表达载体中,通过双荧光素酶报告基因系统检测,发现ZEB1野生型(WT-ZEB1)3'UTR上游报告基因活性受到miR-590-3p调控而表达量下降,而ZEB1突变型(MUT-ZEB1)3'UTR上游报告基因活性不受miR-590-3p调控。通过qRT-PCR与Western blotting验证,ZEB1在蛋白水平受miR-590-3p调控(miR-590-3p mimic的转染浓度为25nM)。
4、ZEB1回复miR-590-3p的功能验证。在心脏成纤维细胞中共转染miR-590-3pinhibitor与si-ZEB1-2后,检测能否回复由miR-590-3p引起的细胞迁移改变。通过Transwell检测结果显示,miR-590-3p inhibitor的促细胞迁移功能可以被si-ZEB1-2回复。
本发明以ZEB1为研究对象,采用细胞生物学方法研究其在人心脏成纤维细胞中的应用。关键点和欲保护点:(1)ZEB1在人心脏成纤维细胞增殖、迁移、分化与胶原合成中的应用;(2)通过靶基因回复验证,即在心脏成纤维细胞中补充抑制ZEB1基因的小干扰RNA片段(si-ZEB1-2)后,验证能否回复由miR-590-3p引起的细胞功能表型。
成纤维细胞的增殖、迁移、分化与合成胶原的能力是影响心肌纤维化的重要机制,本发明第一次证实ZEB1在人心脏成纤维细胞中的应用。本发明补充si-ZEB1-2能够回复由miR-590-3p引起的细胞功能表型,进一步表明ZEB1在成纤维细胞中是miR-590-3p的一个重要功能靶标,miR-590-3p可以通过ZEB1来调节人心脏成纤维细胞的功能。
本发明相对于现有技术具有如下的优点及效果:
本发明以ZEB1为研究对象,合成ZEB1干扰小片段,转染心脏成纤维细胞,发现ZEB1促进心脏成纤维细胞增殖、迁移、分化与胶原合成,还通过控制其表达的miR-590-3p在心脏成纤维细胞中的功能来进行研究;本发明干扰ZEB1后,验证能够回复由miR-590-3p引起的细胞功能表型,表明ZEB1在心脏成纤维细胞中是miR-590-3p的一个重要功能靶标,miR-590-3p可通过ZEB1来调节成纤维细胞的功能。本发明通过ZEB1和其靶向的miRNA在心脏成纤维细胞的应用,对于研究心肌梗死后的纤维化机制具有很好的应用价值。
附图说明
图1是qRT-PCR检测3对ZEB1干扰小片段的干扰效率结果图。
图2是ZEB1干扰小片段(si-ZEB1-2)调控心脏成纤维细胞增殖。
图3是ZEB1干扰小片段(si-ZEB1-2)调控心脏成纤维细胞迁移。
图4是ZEB1干扰小片段(si-ZEB1-2)调控心脏成纤维细胞分化标志基因α-SMA在心脏成纤维细胞中的表达;其中图4A是qRT-PCR结果;图4B是Western blotting结果。
图5是ZEB1干扰小片段(si-ZEB1-2)调控心脏成纤维细胞胶原合成标志基因Col1A1、Col3A1在心脏成纤维细胞中的表达;其中图5A是qRT-PCR结果;图5B是Westernblotting结果。
图6是验证miR-590-3p靶向ZEB1;其中图6A、图6B、图6C分别表示双荧光报告基因验证、qRT-PCR和Western blotting验证。
图7是ZEB1回复miR-590-3p抑制心脏成纤维细胞迁移的结果。
具体实施方式
下面结合实施例及附图对本发明作进一步详细的描述,但本发明的实施方式不限于此。
为了使本发明的目的、技术方案和有益技术效果更加清晰,以下结合实施例,对本发明进行进一步详细说明。应当理解的是,本说明书中描述的实施例仅仅是为了解释本发明,并非为了限定本发明,实施例的参数、比例等可因地制宜做出选择而对结果并无实质性影响。实施例中除特殊说明外,均为本领域常规试剂和方法步骤。
实施例1人心脏成纤维细胞的培养
本实验所用的细胞模型人心脏成纤维细胞来自来自美国ScienCell ResearchLaboratories。所用培养基为美国ScienCell Research Laboratories提供的心脏成纤维细胞培养基(Fibroblast Medium-2)。
(1)实验前准备:a.打开水浴锅,调节温度35.8~37℃;b.超净台开紫外灭菌30min。
(2)从液氮中取出冻存管,迅速浸入37℃水浴锅中,并不时摇动使其尽快融化。
(3)从37℃水浴锅中取出冻存管,外部喷洒75%酒精后转移到超净台,小心打开盖子,用移液枪吸出细胞悬液,加到离心管并滴加10倍以上培养液,混匀。
(4)1000rpm,离心5min。
(5)弃上清,加入完全培养基重悬细胞,接种细胞培养瓶,37℃ 5%CO2培养箱静置培养。
(6)24h后更换新的完全培养基,继续培养。
实施例2人心脏成纤维细胞的接种和转染
(1)镜下观察心脏成纤维细胞汇合度达到90%时,弃培养基,用预热的含1%双抗(双抗为青霉素和链霉素)的PBS清洗细胞两次;
(2)预热的0.25%胰酶加入培养瓶,放入培养箱中静置2min,显微镜下观察到细胞大部分细胞飘起时,加入终止液(10%FBS的DMEM)终止消化。
(3)用枪头轻轻吹打细胞,制成细胞悬液,转移至15mL离心管,1000rpm离心5min。
(4)适量PBS清洗细胞两次。
(5)适量完全培养基重悬细胞沉淀,细胞计数后,均匀分布到每一个孔中,补足完全培养基至推荐的体积,放入培养箱中继续培养。
(6)24h左右观察细胞形态及汇合度,细胞形态良好且汇合度达到70%~90%时,可以用于转染。本发明取第3或第四代传代的心脏成纤维细胞进行转染,转染步骤参照Invitrogen公司的3000试剂盒说明书进行;每组设置3个重复;
(7)转染后,细胞在37℃,5% CO2培养箱中继续培养;
(8)根据实验目的,在转染后的2~4d收集细胞。
实施例3qRT-PCR
(1)冷PBS清洗贴壁细胞2~3次,倾斜细胞培养皿,吸净PBS,加入1mL的Trizol,静置5min,直至镜下观察到细胞全部裂解后,用枪头吹打均匀并转移到1.5mL RNase-free EP管。
(2)每管加入200μL预冷氯仿(Trizol组织液:氯仿为5:1),剧烈震荡15~30s,冰上放置5min后,12000rpm,4℃,离心15min;液体分三层:上层为无色的RNA,中层为含有酚-氯仿的白色水相,下层为浅红色。小心吸取上层无色液相(避免触及中间相)。将上层液相(约300μL)移入新的1.5mL EP管中,加入等量异丙醇溶液(300μL),轻轻上下颠倒摇匀10次,冰上静置10min。12000rpm,4℃,离心10min。
(3)弃上清、留沉淀,沿管壁加入预冷的1mL 75%乙醇-DEPC以洗涤RNA,12000rpm,4℃,离心5min后尽量去上清。
(4)将液体吸干,室温自然干燥5~10min,同时避免RNA沉淀干燥过度。
(5)根据沉淀量,加入30~50μL的DEPC水以溶解RNA沉淀。分光光度计测定RNA浓度和纯度。
逆转录反应采用TAKARA公司的PrimeScriptTM RT Master Mix(Perfect RealTime)Kit。qRT-PCR分别采用Thermo公司的SYBR Green qRT-PCR Master Mix(2X),ROXSolution provided Mix。以2-△△Ct法计算mRNA与miRNA的相对表达量。
本发明所用到的qRT-PCR引物为:
qRT-PCR-α-SMA Forward:5'-GACAATGGCTCTGGGCTCTGTAA-3';
Reverse:5'-CTGTGCTTCGTCACCCACGTA-3';
qRT-PCR-Col1A1Forward:5'-CCCGGGTTTCAGAGACAACTTC-3';
Reverse:5'-TCCACATGCTTTATTCCAGCAATC-3';
qRT-PCR-Col3A1Forward:5'-AATCAGGTAGACCCGGACGA-3';
Reverse:5'-TCGAGCACCGTCATTACCC-3'。
qRT-PCR-GAPDH Forward:5'-GGATTTGGTCGTATTGGG-3';
Reverse:5'-GGAAGATGGTGATGGGATT-3';
qRT-PCR-ZEB1Forward:5'-AACGCTTTTCCCATTCTGGC-3';
Reverse:5'-TTGCCGTATCTGTGGTCGTG-3';
实施例4Western Blotting
(1)人心脏成纤维细胞总蛋白的提取
细胞转染后48h,用PBS清洗细胞3次,6孔板细胞每孔加入100~200μL蛋白裂解液进行蛋白质裂解,细胞裂解液转移到1.5mL EP管中。12000rpm,4℃离心15min,取上清至新的1.5mL EP管中,低温保存防止蛋白降解。
(2)SDS-PAGE电泳
BCA法蛋白样品初步定量后,每组取20μg总蛋白和5×上样缓冲液按5:1混合,煮沸5min。SDS-PAGE电泳至溴酚蓝刚出胶底部止。
(3)转膜
甲醛浸泡聚偏二氟乙烯膜(PVDF膜)5min,清水冲洗后与吸附滤纸一起用转膜液浸泡。从正极开始依次按照吸附滤纸(4张)-凝胶-PVDF膜-吸附滤纸(4张)顺序叠放,合上负极。装入电泳槽中。转膜过程在冰上进行,恒流300mA,根据目的蛋白不同选择转膜时间。
(4)蛋白检测与结果分析
转膜完成后,将膜放入1×TBST中漂洗,用5%脱脂奶粉室温下封闭2h。1×TBST洗膜,用抗体稀释液稀释所需抗体,4℃孵育过夜。回收一抗(ZEB1一抗;α-SMA一抗;Col1A1一抗;Col3A1一抗;上述4个一抗均为常规市售产品),1×TBST洗膜。室温孵育二抗(二抗:辣根过氧化物酶标记山羊抗兔IgG-HRP,购置美国SANTA CRUZ公司)2h。1×TBST洗膜。用ECL化学发光法进行检测,用Bio-Rad曝光系统曝光并采集图片。使用Image J进行电泳条带灰度值测定。
实验例5心脏成纤维细胞增殖实验
本发明中EdU细胞增殖实验参照广州市锐博生物科技有限公司的Cell-LightTMEdU Apollo 567In vitro Kit进行。具体步骤如下(以96孔板为例):
(1)用细胞培养基按1000:1的比例稀释Edu溶液,制备适量浓度为50μM的Edu培养基;
(2)每孔加入100μL浓度为50μM的Edu培养基孵育2h,弃培养基;
(3)PBS清洗细胞1~2次,每次5min;
(4)每孔加入50μL细胞固定液(含4%多聚甲醛的PBS)室温孵育30min,弃固定液;
(5)每孔加入50μL浓度为2mg/mL甘氨酸,脱色摇床孵育5min后,弃甘氨酸溶液;
(6)每孔加入100μL的PBS,脱色摇床清洗5min,弃PBS;
(7)每孔加入100μL的1×Apollo染色反应液,避光、室温、脱色摇床孵育30min后,弃染色反应液;
(8)加入100μL渗透剂(0.5%Triton X的PBS)脱色摇床清洗2~3次,每次5min,弃渗透剂;
(9)用去离子水按100:1的比例稀释试剂F,制备适量1×Hoechst3342反应液,避光保存;
(10)每孔加入100μL的1×Hoechst3342反应液,避光、室温、脱色摇床孵育30min后,弃染色反应液;
(11)每孔加入150μL的PBS清洗1~3次;
(12)每孔加入100μL的PBS保存待用;
(13)染色完成后,用荧光显微镜进行照片采集。
实验例6心脏成纤维细胞迁移实验
本发明使用试剂耗材:Transwell细胞培养板(BD,REF353097)
(1)将细胞培养板放置于室温,PBS润洗培养板内细胞2次,去除培养板内PBS;
(2)加入不含EDTA的胰酶消化细胞,用100μL无血清细胞培养基重悬细胞,计数1×105个细胞,加入Transwell细胞培养板的小室上室,下室加入600μL完全培养基;
(3)在37℃,5%CO2孵育12~48h,取出小室,用棉签擦去上室的细胞,4%多聚甲醛固定细胞20min,PBS洗涤一次,结晶紫染色10min,PBS洗涤一次,显微镜下观察细胞是否穿过小孔,并拍照统计。
实验例7荧光素酶报告基因活性检测
(1)5×PLB室温解冻后,使用ddH2O按1:4的比例将其稀释成1×PLB;
(2)移液枪吸出培养基。沿孔壁慢慢地加入200μL的PBS,轻轻晃动培养板,吸除PBS,此PBS清洗步骤重复两遍,全程注意动作轻柔,防止将细胞吸走;
(3)每孔加入100μL的1×PLB;摇床上孵育10min,使细胞充分裂解;
(4)将裂解的细胞取75μL转移到96孔酶标板中,每孔加入75μL的LARⅡ溶液,混匀后,摇床孵育10min;检测Firefly luciferase荧光强度;
(5)再加入75μL的Stop&Glo溶液,混匀后,摇床孵育10min;检测Ranillaluciferase荧光强度;
(6)Firefly luciferase与Ranilla luciferase的比值即为萤火虫荧光素酶相对活性。(每个组4个重复)。
结果分析:
1、合成3对干扰ZEB1基因小片段/对照(si-ZEB1/si-ZEB1-NC),利用qRT-PCR手段,检测上述片段转染到心脏成纤维细胞之后在细胞中的表达情况(转染浓度为50nM)。结果如图1所示,选择干扰效率最好的si-ZEB1-2进行后续实验。后续统一将si-ZEB1-2与si-ZEB1-NC书写成siZEB1与NC。
si-ZEB1-1:5'-GGCAAGUGUUGGAGAAUAA-3';
si-ZEB1-2:5'-CCAGAAAUACACAGGGUUA-3';
si-ZEB1-3:5'-GGACAGCACAGUAAAUCUA-3';
上述干扰小片段由广州市锐博生物科技有限公司合成。
2、siZEB1转染到心脏成纤维细胞后,研究靶基因ZEB1对心脏成纤维细胞功能的应用。EdU结果如图2所示,siZEB1抑制心脏成纤维细胞增殖,即ZEB1能够促进心脏成纤维细胞增殖。Transwell结果如图3所示,siZEB1抑制心脏成纤维细胞迁移,即ZEB1能够促进心脏成纤维细胞迁移。
3、siZEB1转染到心脏成纤维细胞后,qRT-PCR与Western blotting验证靶基因ZEB1对心脏成纤维细胞分化标志基因α-SMA的作用,结果如图4所示,与对照相比,siZEB1显著抑制α-SMA在mRNA与蛋白的表达,即ZEB1能够促进心脏成纤维细胞中α-SMA的mRNA与蛋白的表达。
4、qRT-PCR与Western blotting验证靶基因ZEB1对心脏成纤维细胞胶原合成标志基因Col1A1与Col3A1的作用,结果如图5所示,与对照相比,siZEB1显著抑制Col1A1与Col3A1在mRNA与蛋白的表达,即ZEB1能够促进心脏成纤维细胞中Col1A1与Col3A1的mRNA与蛋白的表达。
5、利用生物信息学软件预测调控ZEB1的miRNA,发现ZEB1的3'UTR中含有miR-590-3p结合位点,将ZEB1野生型3'UTR和含有种子序列突变的3'UTR构建到真核表达载体pmirGLO中,通过双荧光素酶报告系统分析,发现ZEB1野生型(WT-ZEB1)3'UTR上游报告基因活性受到miR-590-3p调控而表达量下降,而突变型(MUT-ZEB1)载体上报告基因活性则不受miR-590-3p调控(miR-590-3p mimic转染浓度为25nM)。通过qRT-PCR与Western blotting验证,ZEB1在翻译水平受miR-590-3p的调控(miR-590-3p mimic转染浓度为25nM,miR-590-3p inhibitor转染浓度为50nM),结果如图6所示。
6、ZEB1回复miR-590-3p的功能验证。在心脏成纤维细胞同时共转染miR-590-3pinhibitor和siZEB1后,检测能否回复由miR-590-3p引起的细胞功能表型变化。通过Transwell检测心脏成纤维细胞迁移情况,发现miR-590-3p inhibitor引起的促迁移功能可以被siZEB1回复,结果如图7所示。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
序列表
<110> 华南农业大学
广东省实验动物监测所
<120> ZEB1在人心脏成纤维细胞中的应用
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 19
<212> RNA
<213> 人工序列(Artificial Sequence)
<220>
<223> si-ZEB1-1
<400> 1
ggcaaguguu ggagaauaa 19
<210> 2
<211> 19
<212> RNA
<213> 人工序列(Artificial Sequence)
<220>
<223> si-ZEB1-2
<400> 2
ccagaaauac acaggguua 19
<210> 3
<211> 19
<212> RNA
<213> 人工序列(Artificial Sequence)
<220>
<223> si-ZEB1-3
<400> 3
ggacagcaca guaaaucua 19
<210> 4
<211> 21
<212> RNA
<213> 人工序列(Artificial Sequence)
<220>
<223> miR-590-3p
<400> 4
uaauuuuaug uauaagcuag u 21
<210> 5
<211> 23
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-α-SMA Forward
<400> 5
gacaatggct ctgggctctg taa 23
<210> 6
<211> 21
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-α-SMA Reverse
<400> 6
ctgtgcttcg tcacccacgt a 21
<210> 7
<211> 22
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-Col1A1 Forward
<400> 7
cccgggtttc agagacaact tc 22
<210> 8
<211> 24
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-Col1A1 Reverse
<400> 8
tccacatgct ttattccagc aatc 24
<210> 9
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-Col3A1 Forward
<400> 9
aatcaggtag acccggacga 20
<210> 10
<211> 19
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-Col3A1 Reverse
<400> 10
tcgagcaccg tcattaccc 19
<210> 11
<211> 18
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-GAPDH Forward
<400> 11
ggatttggtc gtattggg 18
<210> 12
<211> 19
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-GAPDH Reverse
<400> 12
ggaagatggt gatgggatt 19
<210> 13
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-ZEB1 Forward
<400> 13
aacgcttttc ccattctggc 20
<210> 14
<211> 20
<212> DNA
<213> 人工序列(Artificial Sequence)
<220>
<223> qRT-PCR-ZEB1 Reverse
<400> 14
ttgccgtatc tgtggtcgtg 20
Claims (2)
1.抑制ZEB1基因的siRNA在制备抑制人心脏成纤维细胞ZEB1基因药物中的应用,其特征在于:
抑制ZEB1基因的siRNA,序列如si-ZEB1-1或si-ZEB1-2所示:
si-ZEB1-1:5'-GGCAAGUGUUGGAGAAUAA-3';
si-ZEB1-2:5'-CCAGAAAUACACAGGGUUA-3'。
2.根据权利要求1所述的应用,其特征在于:
在心脏成纤维细胞中补充抑制ZEB1基因的siRNA后,能回复由miR-590-3p引起的细胞功能表型;
所述的miR-590-3p:5'-UAAUUUUAUGUAUAAGCUAGU-3'。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810821050.4A CN108913695B (zh) | 2018-07-24 | 2018-07-24 | Zeb1在人心脏成纤维细胞中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810821050.4A CN108913695B (zh) | 2018-07-24 | 2018-07-24 | Zeb1在人心脏成纤维细胞中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108913695A CN108913695A (zh) | 2018-11-30 |
CN108913695B true CN108913695B (zh) | 2021-10-12 |
Family
ID=64417689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810821050.4A Expired - Fee Related CN108913695B (zh) | 2018-07-24 | 2018-07-24 | Zeb1在人心脏成纤维细胞中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108913695B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112494508A (zh) * | 2020-12-04 | 2021-03-16 | 复旦大学附属中山医院 | microRNA-590-3p在制备治疗抗炎药物中的应用 |
CN113999905B (zh) * | 2021-12-31 | 2022-04-01 | 济南市中心医院 | Hnrnpa2b1在心脏成纤维细胞中的应用 |
WO2024175719A1 (en) * | 2023-02-24 | 2024-08-29 | Syddansk Universitet | Compounds and methods for treating and/or alleviating the side effects of myocardial infarction |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012116111A1 (en) * | 2011-02-22 | 2012-08-30 | Sanford-Burnham Medical Research Institute | METHOD AND COMPOUNDS FOR GENERATION OF iPSCs |
CN105749283A (zh) * | 2016-02-23 | 2016-07-13 | 南开大学 | 基于转录因子zeb1在制备促进乳腺癌化疗敏感性的药物中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106635969A (zh) * | 2016-11-22 | 2017-05-10 | 中国科学院生物物理研究所 | 由干细胞制备心外膜细胞的方法 |
-
2018
- 2018-07-24 CN CN201810821050.4A patent/CN108913695B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012116111A1 (en) * | 2011-02-22 | 2012-08-30 | Sanford-Burnham Medical Research Institute | METHOD AND COMPOUNDS FOR GENERATION OF iPSCs |
CN105749283A (zh) * | 2016-02-23 | 2016-07-13 | 南开大学 | 基于转录因子zeb1在制备促进乳腺癌化疗敏感性的药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108913695A (zh) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108913695B (zh) | Zeb1在人心脏成纤维细胞中的应用 | |
Liu et al. | Overexpression of miR-142-3p improves mitochondrial function in cardiac hypertrophy | |
CN110384800B (zh) | LncRNA XLOC_075168在制备促进血管新生的药物中的应用 | |
Valkov et al. | MicroRNA-1-mediated inhibition of cardiac fibroblast proliferation through targeting cyclin D2 and CDK6 | |
CN113186306A (zh) | 一种与羊的皮肤毛囊成熟相关的miRNA及应用 | |
Chen et al. | Long noncoding RNA (lncRNA) FOXD2-AS1 promotes cell proliferation and metastasis in hepatocellular carcinoma by regulating MiR-185/AKT axis | |
CN114032237A (zh) | 一种环状非编码RNA circSTK39及其在预防和治疗动脉粥样硬化中的应用 | |
CN110484614B (zh) | LncRNA XLOC_057528的抑制剂在制备促进血管新生的药物中的应用 | |
Chen et al. | MiR-1908 improves cardiac fibrosis after myocardial infarction by targeting TGF-β1. | |
Liu et al. | MicroRNA-29c overexpression inhibits proliferation and promotes apoptosis and differentiation in P19 embryonal carcinoma cells | |
Li et al. | Cardiac Fibroblast Activation Induced by Oxygen–Glucose Deprivation Depends on the HIF-1α/miR-212-5p/KLF4 Pathway | |
CN108992457A (zh) | miR-144-3p及其靶基因在制备调节人心脏成纤维细胞功能的药物中的应用 | |
CN115851972A (zh) | 一种绵羊毛囊发育标志物miR-23b及其应用 | |
CN113265428B (zh) | 一种利用金属硫蛋白构建活细胞内铜变化的检测系统及应用 | |
CN112999239B (zh) | 一种高活性抑制idol表达的微小rna的用途 | |
CN115851940A (zh) | 一种骨肉瘤分子标记物及其应用 | |
CN115607689A (zh) | Klf7基因在制备逆转细胞衰老的药物中的应用 | |
CN105624159B (zh) | 一种针对人EDIL3基因的siRNA及其应用 | |
CN110157736B (zh) | 一种促进山羊毛囊干细胞增殖的方法 | |
Yuan et al. | miR‐212 Promotes Cardiomyocyte Hypertrophy through Regulating Transcription Factor 7 Like 2 | |
CN109880828B (zh) | 干扰Mroh7基因表达的siRNA及其应用、干扰方法与药物 | |
CN113980985B (zh) | Ldha在心脏成纤维细胞中的应用 | |
CN110951707A (zh) | 丙酮酸激酶m2突变体及其在心血管疾病中的应用 | |
CN114958849B (zh) | lncRNACACF吸附miR-520b-3p在调控人脐静脉内皮细胞周期中的应用 | |
CN115975916B (zh) | circIGF1R在促进猪骨骼肌卫星细胞成肌分化中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20211012 |
|
CF01 | Termination of patent right due to non-payment of annual fee |